Cargando…

Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines

BACKGROUND: Few studies investigated the concordance in hypertension status and antihypertensive treatment recommendations between the 2018 Chinese Hypertension League (CHL) guidelines and the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines and assessed the chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kangyu, Su, Hao, Wang, Qi, Wu, Zhenqiang, Shi, Rui, Yu, Fei, Yan, Ji, Yuan, Xiaodan, Qin, Rui, Zhou, Ziai, Hou, Zeyi, Li, Chao, Chen, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898956/
https://www.ncbi.nlm.nih.gov/pubmed/35265676
http://dx.doi.org/10.3389/fcvm.2022.784433
_version_ 1784663795922108416
author Chen, Kangyu
Su, Hao
Wang, Qi
Wu, Zhenqiang
Shi, Rui
Yu, Fei
Yan, Ji
Yuan, Xiaodan
Qin, Rui
Zhou, Ziai
Hou, Zeyi
Li, Chao
Chen, Tao
author_facet Chen, Kangyu
Su, Hao
Wang, Qi
Wu, Zhenqiang
Shi, Rui
Yu, Fei
Yan, Ji
Yuan, Xiaodan
Qin, Rui
Zhou, Ziai
Hou, Zeyi
Li, Chao
Chen, Tao
author_sort Chen, Kangyu
collection PubMed
description BACKGROUND: Few studies investigated the concordance in hypertension status and antihypertensive treatment recommendations between the 2018 Chinese Hypertension League (CHL) guidelines and the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines and assessed the change of premature mortality risk with hypertension defined by the ACC/AHA guidelines. METHODS: We used the baseline data of the China Health and Retirement Longitudinal Study (CHARLS) to estimate the population impact on hypertension management between CHL and ACC/AHA guidelines. Mortality risk from hypertension was estimated using the data from China Health and Nutrition Survey (CHNS). Cox proportional hazards model was used to estimate the hazard ratios (HRs) and their 95% confidence intervals(CIs). RESULTS: Among 13,704 participants analyzed from the nationally representative data of CHARLS, 42.64% (95% CI: 40.35, 44.96) of Chinese adults were diagnosed by both CHL and ACC/AHA guidelines. 41.25% (39.17, 43.36) did not have hypertension according to either guideline. Overall, the concordance in hypertension status was 83.89% (81.69, 85.57). A high percentage of agreement was also found for recommendation to initiate treatment among untreated subjects (87.62% [86.67, 88.51]) and blood pressure (BP) above the goal among treated subjects (71.68% [68.16, 74.95]). Among 23,063 adults from CHNS, subjects with hypertension by CHL had a higher risk of premature mortality (1.75 [1.50, 2.04]) compared with those without hypertension. The association diminished for hypertension by ACC/AHA (1.46 [1.07, 1.30]). Moreover, the excess risk was not significant for the newly defined Grade 1 hypertension by ACC/AHA (1.15 [0.95, 1.38]) when compared with BP <120/80 mmHg. This contrasted with the estimate from CHL (1.54 [1.25, 1.89]). The same pattern was observed for total mortality. CONCLUSIONS: If ACC/AHA guidelines were adopted, a high degree of concordance in hypertension status and initiation of antihypertensive treatment was found with CHL guidelines. However, the mortality risk with hypertension was reduced with a non-significant risk for Grade 1 hypertension defined by the ACC/AHA.
format Online
Article
Text
id pubmed-8898956
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88989562022-03-08 Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines Chen, Kangyu Su, Hao Wang, Qi Wu, Zhenqiang Shi, Rui Yu, Fei Yan, Ji Yuan, Xiaodan Qin, Rui Zhou, Ziai Hou, Zeyi Li, Chao Chen, Tao Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Few studies investigated the concordance in hypertension status and antihypertensive treatment recommendations between the 2018 Chinese Hypertension League (CHL) guidelines and the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines and assessed the change of premature mortality risk with hypertension defined by the ACC/AHA guidelines. METHODS: We used the baseline data of the China Health and Retirement Longitudinal Study (CHARLS) to estimate the population impact on hypertension management between CHL and ACC/AHA guidelines. Mortality risk from hypertension was estimated using the data from China Health and Nutrition Survey (CHNS). Cox proportional hazards model was used to estimate the hazard ratios (HRs) and their 95% confidence intervals(CIs). RESULTS: Among 13,704 participants analyzed from the nationally representative data of CHARLS, 42.64% (95% CI: 40.35, 44.96) of Chinese adults were diagnosed by both CHL and ACC/AHA guidelines. 41.25% (39.17, 43.36) did not have hypertension according to either guideline. Overall, the concordance in hypertension status was 83.89% (81.69, 85.57). A high percentage of agreement was also found for recommendation to initiate treatment among untreated subjects (87.62% [86.67, 88.51]) and blood pressure (BP) above the goal among treated subjects (71.68% [68.16, 74.95]). Among 23,063 adults from CHNS, subjects with hypertension by CHL had a higher risk of premature mortality (1.75 [1.50, 2.04]) compared with those without hypertension. The association diminished for hypertension by ACC/AHA (1.46 [1.07, 1.30]). Moreover, the excess risk was not significant for the newly defined Grade 1 hypertension by ACC/AHA (1.15 [0.95, 1.38]) when compared with BP <120/80 mmHg. This contrasted with the estimate from CHL (1.54 [1.25, 1.89]). The same pattern was observed for total mortality. CONCLUSIONS: If ACC/AHA guidelines were adopted, a high degree of concordance in hypertension status and initiation of antihypertensive treatment was found with CHL guidelines. However, the mortality risk with hypertension was reduced with a non-significant risk for Grade 1 hypertension defined by the ACC/AHA. Frontiers Media S.A. 2022-02-21 /pmc/articles/PMC8898956/ /pubmed/35265676 http://dx.doi.org/10.3389/fcvm.2022.784433 Text en Copyright © 2022 Chen, Su, Wang, Wu, Shi, Yu, Yan, Yuan, Qin, Zhou, Hou, Li and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Chen, Kangyu
Su, Hao
Wang, Qi
Wu, Zhenqiang
Shi, Rui
Yu, Fei
Yan, Ji
Yuan, Xiaodan
Qin, Rui
Zhou, Ziai
Hou, Zeyi
Li, Chao
Chen, Tao
Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines
title Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines
title_full Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines
title_fullStr Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines
title_full_unstemmed Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines
title_short Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines
title_sort similarities in hypertension status but differences in mortality risk: a comparison of 2017 acc/aha and 2018 chinese hypertension guidelines
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898956/
https://www.ncbi.nlm.nih.gov/pubmed/35265676
http://dx.doi.org/10.3389/fcvm.2022.784433
work_keys_str_mv AT chenkangyu similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT suhao similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT wangqi similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT wuzhenqiang similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT shirui similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT yufei similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT yanji similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT yuanxiaodan similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT qinrui similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT zhouziai similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT houzeyi similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT lichao similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines
AT chentao similaritiesinhypertensionstatusbutdifferencesinmortalityriskacomparisonof2017accahaand2018chinesehypertensionguidelines